SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (Skye), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
SAN DIEGO, April 23, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (Skye), a clinical-stage biotechnology company focused on the discovery, development and commercialization of...
Skye Bioscience uplists to the Nasdaq: The San Diego biotech $SKYE is set to make the move from the OTC markets on Thursday. Earlier this year, it raised a total of about $90 million in private placements. Skye recently completed enrollment in a Phase 2a trial in glaucoma and ocular hypertension, and it plans to start an obesity and chronic kidney disease study in the middle of this year. — Kyle LaHucik
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
Skye files IND with FDA Division of Diabetes, Lipid Disorders and Obesity Phase 2 study in patients with obesity and chronic kidney disease planned to initiate in first half of 2024 SAN DIEGO, Dec. ...
SBI-100 Ophthalmic Emulsion, a CB1 agonist/activator delivered as a topical eye drop, was developed to treat patients with elevated intraocular pressurePhase 2 study evaluating efficacy and safety...
Skye Bioscience acquired Bird Rock Bio to get its hands on an asset targeting CB1 just two weeks after Novo Nordisk dipped its toes into the once-hot space to buy Inversago Pharma, another developer of CB1 therapies.
US-based biopharmaceutical company Skye Bioscience has finished enrolling patients in its Phase I trial of SBI-100 Ophthalmic Emulsion (OE), a cannabinoid receptor type 1 (CB1R) agonist that is given topically onto the eye.